[go: up one dir, main page]
KEGG   DRUG: Canakinumab
Entry
D09315                      Drug                                   
Name
Canakinumab (USAN/INN);
Canakinumab (genetical recombination) (JAN);
Ilaris (TN)
Product
ILARIS (Novartis Pharmaceuticals Corporation)
Formula
C6452H9958N1722O2010S42
Exact mass
145065.8205
Mol weight
145155.24
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC08
Product: D09315<JP/US>
Efficacy
Anti-inflammatory disease, Anti-IL-1 beta antibody
  Disease
Cryopyrin-associated periodic syndromes [DS:H00282]
Tumor necrosis factor receptor associated periodic syndrome [DS:H00912]
Hyperimmunoglobulin D syndrome /Mevalonate kinase deficiency [DS:H00206]
Familial mediterranean fever [DS:H00288]
Systemic juvenile idiopathic arthritis [DS:H01672]
  Type
Monoclonal antibody
Target
IL1B [HSA:3553] [KO:K04519]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04621  NOD-like receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC08 Canakinumab
      D09315  Canakinumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Canakinumab
     D09315  Canakinumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D09315  Canakinumab (USAN/INN); Canakinumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09315  Canakinumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09315  Canakinumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL1B
     D09315  Canakinumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09315
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09315
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09315
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09315
Other DBs
CAS: 914613-48-2
PubChem: 96025995
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system